(Q44869105)

7 December 2017

0 references

Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials (English)

1 reference

7 December 2017

1 reference

1 reference

6

1 reference

7 December 2017

10

1 reference

7 December 2017

Emilio Bria

2

0 references

author name string

Federica Cuppone

1

1 reference

7 December 2017

Paolo Carlini

3

1 reference

7 December 2017

Michele Milella

4

1 reference

7 December 2017

Alessandra Felici

5

1 reference

7 December 2017

Cecilia Nisticò

7

1 reference

7 December 2017

Edmondo Terzoli

8

1 reference

7 December 2017

Francesco Cognetti

9

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 July 2008

1 reference

7 December 2017

1 reference

7 December 2017

volume

113

1 reference

7 December 2017

issue

2

1 reference

7 December 2017

page(s)

238-246

1 reference

Confidence intervals for the number needed to treat

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Preoperative (neoadjuvant) systemic treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Benefit of taxanes as adjuvant chemotherapy for early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Interpreting Measures of Treatment Effect in Cancer Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Global gene expression changes during neoadjuvant chemotherapy for human breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23544

7 January 2021

Identifiers

DOI

10.1002/CNCR.23544

1 reference

7 December 2017

1 reference